Tsutomu Takeuchi

54.1k total citations · 7 hit papers
1.2k papers, 30.6k citations indexed

About

Tsutomu Takeuchi is a scholar working on Rheumatology, Genetics and Immunology. According to data from OpenAlex, Tsutomu Takeuchi has authored 1.2k papers receiving a total of 30.6k indexed citations (citations by other indexed papers that have themselves been cited), including 586 papers in Rheumatology, 230 papers in Genetics and 217 papers in Immunology. Recurrent topics in Tsutomu Takeuchi's work include Rheumatoid Arthritis Research and Therapies (386 papers), Systemic Lupus Erythematosus Research (241 papers) and Chronic Lymphocytic Leukemia Research (208 papers). Tsutomu Takeuchi is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (386 papers), Systemic Lupus Erythematosus Research (241 papers) and Chronic Lymphocytic Leukemia Research (208 papers). Tsutomu Takeuchi collaborates with scholars based in Japan, United States and United Kingdom. Tsutomu Takeuchi's co-authors include Yoshiya Tanaka, Nobuyuki Miyasaka, Yuko Kaneko, Hisashi Yamanaka, Kazuhiko Yamamoto, Hideto Kameda, M. Tanabe, Shinichi Kawai, Tadamitsu Kishimoto and Hitoshi Umezawa and has published in prestigious journals such as Nature, Cell and JAMA.

In The Last Decade

Tsutomu Takeuchi

1.1k papers receiving 29.7k citations

Hit Papers

Innate production of TH... 1966 2026 1986 2006 2009 2004 1966 2007 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells
    2009 1.6k citations Kazuyo Moro, Taketo Yamada et al. Nature profile →
  2. Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trial
    2004 630 citations Nobuyuki Miyasaka, Kazuhiko Yamamoto et al. profile →
  3. New antibiotics, bleomycin A and B.
    1966 612 citations Tsutomu Takeuchi et al. PubMed profile →
  4. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
    2007 582 citations Kazuhiko Yamamoto, Tsutomu Takeuchi et al. Annals of the Rheumatic Diseases profile →
  5. Translating IL-6 biology into effective treatments
    2020 441 citations Tsutomu Takeuchi et al. profile →
  6. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
    2016 309 citations Désirée van der Heijde, Tsutomu Takeuchi et al. Arthritis & Rheumatology profile →
  7. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
    2019 224 citations Mark C. Genovese, Jacques‐Eric Gottenberg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tsutomu Takeuchi Japan 81 12.5k 8.9k 4.8k 4.5k 3.7k 1.2k 30.6k
T. Huizinga Netherlands 113 28.4k 2.3× 14.7k 1.7× 6.9k 1.4× 6.6k 1.5× 3.6k 1.0× 1.1k 49.4k
Peter E. Lipsky United States 107 13.8k 1.1× 23.2k 2.6× 4.6k 1.0× 8.4k 1.9× 2.8k 0.7× 661 46.7k
David Isenberg United Kingdom 102 27.9k 2.2× 22.8k 2.6× 4.5k 0.9× 6.0k 1.3× 4.6k 1.2× 969 45.8k
Iain B. McInnes United Kingdom 112 24.4k 1.9× 25.5k 2.9× 10.3k 2.2× 12.2k 2.7× 4.1k 1.1× 738 58.4k
Georg Schett Germany 118 22.5k 1.8× 18.0k 2.0× 6.1k 1.3× 21.6k 4.8× 3.7k 1.0× 1.1k 59.6k
Peter Valent Austria 97 8.6k 0.7× 16.7k 1.9× 9.6k 2.0× 9.7k 2.2× 1.2k 0.3× 900 40.5k
Eng M. Tan United States 86 17.7k 1.4× 14.5k 1.6× 2.0k 0.4× 11.1k 2.5× 5.4k 1.4× 331 40.8k
Paul Emery United Kingdom 123 45.9k 3.7× 18.2k 2.1× 17.3k 3.6× 5.8k 1.3× 3.7k 1.0× 1.0k 67.0k
Dennis A. Carson United States 88 3.0k 0.2× 11.1k 1.3× 1.5k 0.3× 11.4k 2.6× 3.0k 0.8× 467 29.3k
Alan S. Cohen United States 61 11.6k 0.9× 6.5k 0.7× 1.6k 0.3× 9.5k 2.1× 2.3k 0.6× 265 25.8k

Countries citing papers authored by Tsutomu Takeuchi

Since Specialization
Citations

This map shows the geographic impact of Tsutomu Takeuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsutomu Takeuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsutomu Takeuchi more than expected).

Fields of papers citing papers by Tsutomu Takeuchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsutomu Takeuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsutomu Takeuchi. The network helps show where Tsutomu Takeuchi may publish in the future.

Co-authorship network of co-authors of Tsutomu Takeuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Tsutomu Takeuchi. A scholar is included among the top collaborators of Tsutomu Takeuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsutomu Takeuchi. Tsutomu Takeuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matsumoto, Kotaro, Hiroto Yoshida, Masaru Takeshita, et al.. (2025). Trans-omics landscape of systemic vasculitis identified matrix metalloproteinase 12 as a novel signature molecule. Lara D. Veeken. 64(8). 4766–4775. 1 indexed citations
2.
Okamoto, Nami, Tatsuya Atsumi, Michiaki Takagi, et al.. (2024). Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study. Modern Rheumatology. 35(2). 215–224. 6 indexed citations
3.
Burmester, Gerd R, Jacques‐Eric Gottenberg, Roberto Caporali, et al.. (2024). Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years. Annals of the Rheumatic Diseases. 83(9). 1110–1117. 9 indexed citations
4.
Saito, Shuntaro, Hironari Hanaoka, Jun Kikuchi, et al.. (2024). Urinary Biomarkers Associated With Pathogenic Pathways Reflecting Histologic Findings in Lupus Nephritis. Arthritis & Rheumatology. 77(3). 298–310. 3 indexed citations
5.
Buch, Maya H, Daniel Aletaha, Bernard Combe, et al.. (2024). Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study. RMD Open. 10(4). e004476–e004476. 1 indexed citations
6.
Felten, Renaud, Tao Ye, Benno Schwikowski, et al.. (2023). Identification of new candidate drugs for primary Sjögren’s syndrome using a drug repurposing transcriptomic approach. Lara D. Veeken. 62(11). 3715–3723. 6 indexed citations
7.
Takagi, Michiaki, Tatsuya Atsumi, Hiroaki Matsuno, et al.. (2022). Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. Modern Rheumatology. 33(4). 647–656. 17 indexed citations
8.
Kimoto, Yasutaka, Takuya Sawabe, Masahiro Ayano, et al.. (2022). Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study. Modern Rheumatology. 33(2). 367–372. 9 indexed citations
9.
Tanaka, Yoshiya, Satoshi Soen, Naoki Ishiguro, et al.. (2020). Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. RMD Open. 6(2). e001249–e001249. 7 indexed citations
10.
11.
12.
Tahir, Hasan, Atul Deodhar, Mark C. Genovese, et al.. (2017). Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. Rheumatology and Therapy. 4(2). 475–488. 27 indexed citations
13.
14.
Sugano, Kentaro, et al.. (2012). Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti‐inflammatory drug‐related peptic ulcers in J apanese patients. Alimentary Pharmacology & Therapeutics. 36(2). 115–125. 24 indexed citations
15.
Moro, Kazuyo, Taketo Yamada, M. Tanabe, et al.. (2009). Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature. 463(7280). 540–544. 1558 indexed citations breakdown →
16.
Kameda, Hideto, Hayato Nagasawa, Hiroe Ogawa, et al.. (2005). Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.. PubMed. 32(9). 1719–26. 178 indexed citations
17.
Haghighi, Ali, Seiki Kobayashi, Tsutomu Takeuchi, Gohta MASUDA, & Tomoyoshi Nozaki. (2002). Remarkable Genetic Polymorphism among Entamoeba histolytica Isolates from a Limited Geographic Area. Journal of Clinical Microbiology. 40(11). 4081–4090. 86 indexed citations
18.
Ahmed, S., Kenji Ihara, Shigeru Kanemitsu, et al.. (2001). Association of CTLA‐4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population. Lara D. Veeken. 40(6). 662–667. 127 indexed citations
19.
Tanabe, M., et al.. (1990). Estudo sorológico na esquistosomíase mansônica no nordeste do Brasil. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas). 8 indexed citations
20.
Morita, Daisuke, et al.. (1962). A Case Report on Human Infection with Plagiorchis muris in Japan.. Kiseichūgaku zasshi. 11(6). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Huizinga Breakdown of academic impact, for papers by Peter E. Lipsky Breakdown of academic impact, for papers by David Isenberg Breakdown of academic impact, for papers by Iain B. McInnes Breakdown of academic impact, for papers by Georg Schett Breakdown of academic impact, for papers by Peter Valent Breakdown of academic impact, for papers by Eng M. Tan Breakdown of academic impact, for papers by Paul Emery Breakdown of academic impact, for papers by Dennis A. Carson Breakdown of academic impact, for papers by Alan S. Cohen
Rankless by CCL
2026